Loading
Life sciences · Journal article
Holistic Integrative Oncology · October 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Hepatocellular carcinoma (HCC) remains the third leading cause of cancer-related mortality worldwide, accounting for over 85% of primary liver cancers. Locoregional ablation techniques—encompassing thermal modalities such as radiofrequency ablation (RFA) and microwave ablation (MWA), and non-thermal approaches including cryoablation (CA) and irreversible electroporation (IRE)—have been established as standard-of-care options for early-stage HCC. Ablation induces immunogenic cell death (ICD), releasing tumor-associated antigens (TAAs) and damage-associated molecular patterns (DAMPs) that prime antitumor immunity; however, this response is transient and insufficient to overcome the immunosuppressive tumor immune microenvironment (TIME), necessitating combination with immunotherapy. While preclinical evidence supports ablation-immunotherapy synergy across multiple platforms, robust phase III clinical data demonstrating survival benefit remain limited. This review systematically summarizes the immunological mechanisms underlying tumor ablation, and primarily discusses: (1) Modality-specific immune profiles—thermal ablation induces broad DAMP release but is limited by antigen denaturation and by incomplete ablation (iRFA), which associates with SUMO2-mediated IFN-I suppression, whereas non-thermal modalities (CA, IRE) preserve antigen conformation and engage multiple regulated cell death pathways; (2) Comprehensive combination strategies addressing three immunological barriers: innate APC licensing (PRR agonists, STING, GM-CSF, nanobiomaterials), T cell priming and trafficking (immune checkpoint inhibitors and adoptive cell therapy), and systemic memory durability (oncolytic viruses); (3) Critical mechanistic barriers to clinical translation: iRFA paradoxically couples residual tumor substrate with immunosuppression; the post-ablation immune activation window (3–14 days) remains clinically unexploited; and mechanistic understanding substantially outpaces clinical validation. Collectively, these advances support the continued development of personalized and precision-guided ablation–immunotherapy strategies for HCC.